AzTrials
AzTrials

Condition

Weight Loss Clinical Trials

Studies of weight loss, matched by condition name and medical subject headings. Start with those open to enrolment.

1,835 registered studies

In numbers

Open to volunteers
259
Active
334
With results posted
258
All registered
1,835

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 259
  • Liver Cirrhoses, Portal Hypertension Related to Cirrhosis

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    • Recruiting
    • Age: 18 to 70 years
    • Phase 4
    • Surgery or procedure
    • Lifestyle or therapy programme

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.

    Conditions
    Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
    Trial name
    OPTIMAL (NCT07058155)
    Testing
    Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
    Where
    United States
    Volunteers
    70 people
    Sponsor
    The Cleveland Clinic
    Can I take part? OPTIMAL
  • Cachexia; Cancer, Cachexia

    OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 2/3
    • Injection or infusion

    The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.

    Conditions
    Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
    Trial name
    REACH-OLE (NCT07888075)
    Testing
    Rilogrotug
    Volunteers
    400 people
    Sponsor
    AVEO Pharmaceuticals, Inc.
    Can I take part? REACH-OLE
  • Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss

    Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 1/2
    • Injection or infusion

    This is a Phase 1b/2, multi-site, single-arm, open-label, non-randomized study looking at whether adding tocilizumab to standard treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) is safe, possible, and effective.

    Conditions
    Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers
    Trial name
    TOCI (NCT07889232)
    Testing
    Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy
    Where
    4 sites in United States
    Volunteers
    43 people
    Sponsor
    VA Office of Research and Development
    Can I take part? TOCI
  • Obesity, Overweight

    A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

    • Not yet recruiting
    • Age: 18 to 75 years
    • Phase 2
    • Pill or oral medicine

    The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…

    Trial name
    NCT07890376
    Testing
    LY4086940
    Where
    46 sites in United States, Argentina
    Volunteers
    460 people
    Sponsor
    Eli Lilly and Company
    Can I take part? NCT07890376
  • Pancreatic Adenocarcinoma, Weight Loss

    Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

    • Recruiting
    • Age: 18 years and older
    • Observational study

    The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status.

    Trial name
    SIBO in PDAC (NCT06988150)
    Where
    United States
    Volunteers
    100 people
    Sponsor
    Cedars-Sinai Medical Center
  • Obesity (BMI>30)

    Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

    • Recruiting
    • Age: 18 to 60 years
    • Phase 4
    • Lifestyle or therapy programme

    Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is…

    Trial name
    RESIST (NCT07777575)
    Testing
    Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance Training
    Where
    Germany
    Volunteers
    150 people
    Sponsor
    Technical University of Munich
    Can I take part? RESIST
  • Prediabetes, Weight Loss

    Diabetes Prevention Through Genetics, Familial History and Behavior Change

    • Not yet recruiting
    • Age: 18 to 75 years
    • Phase 2/3
    • Lifestyle or therapy programme

    The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes.

    Trial name
    NCT07815236
    Testing
    LEGACY DPP, DPP
    Volunteers
    400 people, healthy volunteers welcome
    Sponsor
    Morehouse School of Medicine
    Can I take part? NCT07815236
  • Bariatric Surgery, Sleeve Gastrectomy

    15-years Outcomes of Sleeve Gastrectomy on Weight Loss

    • Recruiting
    • Age: 18 years and older
    • Observational study

    Evaluate the beneficial and harmful effects of sleeve gastrectomy at 15 years in a pioneering center for this surgical technique in France

    Conditions
    Bariatric Surgery, Sleeve Gastrectomy, Weight Loss
    Trial name
    SLEEVE15 (NCT07883018)
    Where
    France
    Volunteers
    300 people
    Sponsor
    Centre Hospitalier Universitaire, Amiens
    Can I take part? SLEEVE15
  • Weight Loss

    Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 3
    • Pill or oral medicine

    This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type…

    Trial name
    NCT07868835
    Testing
    VK2735
    Volunteers
    560 people
    Sponsor
    Viking Therapeutics, Inc.
    Can I take part? NCT07868835
  • Weight Loss

    Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 3
    • Pill or oral medicine

    This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

    Trial name
    NCT07868939
    Testing
    VK2735 Oral
    Volunteers
    560 people
    Sponsor
    Viking Therapeutics, Inc.
    Can I take part? NCT07868939

Completed, with results posted

All –
  • Hypogonadism, Hypogonadotropic, Obesity

    Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

    • Completed
    • Age: 40 to 65 years
    • Phase 4
    • Pill or oral medicine
    • Results posted

    The investigators have preliminary data suggesting that obese patients with hypogonadotropic hypogonadism (HHG) have minimal benefit from testosterone therapy likely because of its conversion to estradiol by the abundant…

    Trial name
    NCT03490513
    Testing
    anastrozole (1 mg/day)
    Where
    United States
    Volunteers
    121 people
    Sponsor
    Baylor College of Medicine
    Can I take part? NCT03490513
  • Obesity, Weight Loss

    Project Activate: Mindfulness and Acceptance Based Behavioral Treatment for Weight Loss

    • Completed
    • Age: 18 to 70 years
    • Lifestyle or therapy programme
    • Results posted

    Mindfulness and Acceptance based Behavioral Therapies (MABTs) are among the most promising behavioral approaches for obesity, with two recent large trials showing that they achieve better initial weight loss and/or better weight…

    Trial name
    Activate (NCT04337619)
    Testing
    Behavioral Treatment, Willingness, Values
    Where
    United States
    Volunteers
    276 people
    Sponsor
    Drexel University
    Can I take part? Activate
  • Pre Diabetes, Weight Loss

    Integrated Community-Clinical Linkage Model to Promote Weight Loss Among South Asians With Pre-Diabetes

    • Completed
    • Age: 21 to 75 years
    • Lifestyle or therapy programme
    • Results posted

    The study "Integrated Community-Clinical Linkage Model to Promote Weight Loss among South Asians with Pre-Diabetes" is a two-arm randomized control trial that analyzes the implementation and effectiveness of a multi-component…

    Trial name
    NCT03188094
    Testing
    CHW-Led Health Coaching, EHR Alerts
    Where
    United States
    Volunteers
    974 people
    Sponsor
    NYU Langone Health
  • Overweight, Obesity

    Sharing Digital Self-Monitoring Data With Others to Enhance Long-Term Weight Loss

    • Completed
    • Age: 18 to 70 years
    • Lifestyle or therapy programme
    • Results posted

    Adults attempting weight loss through lifestyle modification (LM) typically find maintenance of behavior change difficult. Outcomes might be improved if participants are provided with sustained sources of accountability and…

    Trial name
    FitLink (NCT05180448)
    Testing
    Coach Share On, Group Share On, Friend/Family Share On
    Where
    United States
    Volunteers
    321 people, healthy volunteers welcome
    Sponsor
    Drexel University
    Can I take part? FitLink
  • Cancer Prevention, Weight Loss

    PROFAST Intervention in Precursor Multiple Myeloma

    • Completed
    • Age: 18 years and older
    • Lifestyle or therapy programme
    • Results posted

    This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…

    Conditions
    Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
    Trial name
    PROFAST (NCT05565638)
    Testing
    Prolonged Fasting Intervention, EDUCATION CONTROL
    Where
    United States
    Volunteers
    23 people
    Sponsor
    Dana-Farber Cancer Institute
    Can I take part? PROFAST

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in